<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433587</url>
  </required_header>
  <id_info>
    <org_study_id>08-14-29</org_study_id>
    <nct_id>NCT02433587</nct_id>
  </id_info>
  <brief_title>Short vs Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization</brief_title>
  <official_title>Evaluation of Short Versus Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the trial is to evaluate short versus long duration dual
      antiplatelet therapy in patients undergoing lower extremity endovascular revascularization.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Never recruited any patients.
  </why_stopped>
  <start_date type="Anticipated">October 2019</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiovascular Event Rates</measure>
    <time_frame>12 months post-intervention</time_frame>
    <description>Stroke, Myocardial Infarction, Cardiovascular Death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Adverse Limb Event Rates</measure>
    <time_frame>12 months post-intervention</time_frame>
    <description>Severe limb ischemia leading to a reintervention or major vascular amputation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Outcome</measure>
    <time_frame>12 Months post-intervention</time_frame>
    <description>Assessed by Intermittent Claudication Questionnaire and Short Form-36 Health Survey</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Endovascular Procedures</condition>
  <arm_group>
    <arm_group_label>Short Term</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The short term group will continue Aspirin 81mg and Clopidogrel 75mg for 1 month after the intervention. After that, they will continue Aspirin 81mg only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long Term</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The long term group will continue Aspirin 81mg and Clopidogrel 75mg for 6 months after the intervention. After this time, they will continue on Aspirin 81mg only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Patients will take Aspirin 81 mg</description>
    <arm_group_label>Long Term</arm_group_label>
    <arm_group_label>Short Term</arm_group_label>
    <other_name>Acetylsalicylic acid (ASA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Patients will take Clopidogrel 75 mg</description>
    <arm_group_label>Long Term</arm_group_label>
    <arm_group_label>Short Term</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide signed informed consent before initiation of any study related procedures

          2. Be at least 18 years of age

          3. Successful percutaneous lower extremity (iliac and infrainguinal) endovascular
             revascularization (percutaneous transluminal angioplasty, and /or stent).

          4. At least 1 vessel run-off in segment distal to the intervention

          5. Rutherford Classification 2-5 that is unresponsive to medical therapy

        Exclusion Criteria:

          1. Acute limb ischemia

          2. Procedure includes device deployment that has specific FDA regulations for
             anticoagulation/anti-platelet medication regimen.

          3. Patient undergoing atherectomy procedure

          4. Intervention includes deployment of drug eluted stent

          5. Critical limb ischemia (Rutherford Classification 6)

          6. Thrombocytopenia: Platelet count &lt;50k

          7. Liver disease (Childs-Pugh B or C)

          8. Existing need for on going clopidogrel therapy

          9. Proton Pump Inhibitor Use (If unable to be switched)

         10. Need for therapeutic anticoagulation

         11. Known hypercoagulable disorder

         12. Allergy or contraindication to aspirin or clopidogrel

         13. Pregnancy

         14. Patients enrolled in another investigational drug or device study within the past 30
             days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>April 29, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2015</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Vikram S. Kashyap, M.D.</investigator_full_name>
    <investigator_title>Chief, Division of Vascular Surgery &amp; Endovascular Therapy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

